pharmaphorum

APRIL 27, 2022

AstraZeneca and Daiichi Sankyo have claimed a fifth breakthrough designation from the FDA for Enhertu, shortly after showing the drug extended survival in patients with HER2-low metastatic breast cancer. The post Enhertu gets breakthrough tag in HER2-low breast cancer appeared first on.

Chemotherapy 57

Chemotherapy FDA 57

Pharmaceutical Technology

MAY 2, 2023

Immuno-oncology (IO) agents have transformed the cancer therapeutics landscape, driving long-term remissions in a subset of patients who historically had limited options. Although a subset of patients derives long-term benefits from IO therapies, a high percentage of patients still fail to respond or develop resistance to IO therapy.

Immunization 52

Immunization Vaccines 52

DiversifyRx

JUNE 23, 2023

I used to email every patient manually because I had so few. Your CRM can help nurture a potential patient, from knowing very little about you and what you do to getting to know you, understanding how you can help them, and wanting to become your patient. It offers segmentation, tagging, and scheduling capabilities.

52

52

Pharmaceutical Technology

JULY 14, 2022

Historically, the pharmaceutical industry has failed to meet the needs of this patient population. Most famously, the US passed its Orphan Drug Act in 1983, providing innovators with financial motivation to develop orphan drugs and meet the needs of these forgotten patients. Efforts have been made to change this.

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceutical Companies Hospitals 59

Pharmaceutical Technology

APRIL 5, 2023

More than a decade after the first patient was treated with a CAR-T therapy, six therapies relying on the same principles have been approved by the US Food and Drug Administration (FDA) and marketed to thousands of patients. How can we better educate the patients? How has the field changed in recent years?

FDA 59

FDA Immunization 59

The Checkup by Singlecare

SEPTEMBER 7, 2023

Still, more recently, Glucagon-like peptide-1 receptor agonists (GLP-1-RA) have become the first-line treatment for those patients with established atherosclerotic coronary vascular disease (ASCVD). There are other choices for Mounjaro, whether it is being used to treat diabetes or help lower body weight (or both).

Insurance 52

Insurance Insurance Coverage FDA Dosage 52

Viseven

FEBRUARY 6, 2023

The number of such tools is growing in quantity and quality; this tendency allows the target audience to be more flexible in their choices. Patients and healthcare providers strongly require an individual approach for various reasons like time restrictions or personal specifics. Yes, we are talking about personalization.

Communication 75

Communication 75